Walmart has agreed to settle a federal lawsuit brought by the U.S. government that alleged the retailer’s pharmacies improperly dispensed opioid prescriptions, the Department of Justice said on Friday. The parties did not disclose the terms of the settlement.
The Justice Department originally filed suit in 2020, accusing the Bentonville, Arkansas-based company of repeated violations of the federal Controlled Substances Act dating back to 2013. At the time the government said Walmart could face civil penalties potentially reaching into the billions of dollars.
"The department is pleased to have reached a settlement with Walmart resolving allegations that its pharmacies failed to comply with their obligations under the Controlled Substances Act in dispensing opioids and other controlled substances," a Justice Department spokesperson said.
Walmart issued a brief statement acknowledging the resolution and praising its pharmacy staff. "We are pleased to resolve this matter and will continue supporting the exceptional work our pharmacists do every day to provide outstanding patient care," the company said.
Earlier this year, U.S. District Judge Colm Connolly narrowed the government's case. In March 2024, Connolly dismissed claims that Walmart failed to report suspicious prescriptions to the U.S. Drug Enforcement Administration and that pharmacists did not document so-called "red flags" tied to prescriptions. The judge allowed the government to proceed with a claim that pharmacists filled prescriptions that Walmart compliance personnel believed were invalid. A separate claim alleging that pharmacists themselves knowingly dispensed invalid prescriptions also remained pending.
Legal observers had noted the case as among the most consequential Justice Department actions focused on a single company linked to the opioid epidemic. Walmart had previously reached agreements to resolve other litigation related to pharmacy practices. In 2022 the company agreed to pay $3.1 billion to settle thousands of suits brought by state and local governments over its pharmacies' role in the crisis.
The federal action against Walmart was part of a broader wave of legal activity that also targeted other industry participants. The government pursued claims against Purdue Pharma, which entered a guilty plea in 2020 tied to its painkiller OxyContin after filing for bankruptcy protection, and the drug wholesaler Cencora, formerly known as AmerisourceBergen.
The Department of Health statistics cited by government authorities in related litigation point to substantial mortality tied to opioid overdoses. According to figures referenced by the government, more than 905,000 people died from opioid overdoses between 1999 and 2025, and annual deaths began to decline after 2022.
Context and implications
This settlement closes a major federal civil case alleging long-running noncompliance with the Controlled Substances Act by a national pharmacy operator, although public details on remedies or financial terms were not provided. The docket had already been pared back by judicial rulings earlier in 2024, leaving specific allegations about the validity of filled prescriptions as the principal unresolved claims prior to settlement.